Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.63 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.61 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.54 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.53 |
| ▸ | AHR | P35869 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32679648 | 1.00 | HTR2A (0.63) | HTR2AGPR84KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL15453266 | 0.90 | HTR2A (0.59) | HTR2AGPR84KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL6939255 | 0.83 | HTR2A (0.63) | HTR2AGPR84KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL29955437 | 0.83 | GPR84 (0.65) | HTR2AGPR84KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL2010595 | 0.83 | GPR84 (0.65) | HTR2AGPR84KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL28680598 | 0.82 | HTR2A (0.66) | HTR2AGPR84KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL18328036 | 0.81 | HTR2A (0.69) | HTR2AGPR84KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL7004405 | 0.80 | HTR2A (0.73) | HTR2AGPR84KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL9889542 | 0.79 | HTR2A (0.71) | HTR2AGPR84KEAP1NFE2L2ALDH1A1 | |
| SCHEMBL256689 | 0.78 | GPR84 (0.74) | HTR2AGPR84KEAP1NFE2L2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12454502-B2 | Synthesis of deuterated aldehydes | ARIZONA BOARD OF REGENTS ON BEHALF OF ATHE UNIVERSITY OF ARIZONA (US) | 2025-10-28 | — | — | US | disclosed |
| US-20220356139-A1 | SYNTHESIS OF DEUTERATED ALDEHYDES | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2022-11-10 | — | — | US | disclosed |
| WO-2021045879-A1 | SYNTHESIS OF DEUTERATED ALDEHYDES | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2021-03-11 | — | — | WO | disclosed |
| US-20140039171-A1 | NOVEL MACROLIDE INTERMEDIATE AND NOVEL PRODUCTION PROCESS | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-02-06 | — | — | US | disclosed |
| EP-2682399-A1 | NOVEL MACROLIDE INTERMEDIATE AND NOVEL PRODUCTION PROCESS | Meiji Seika Pharma Co., Ltd. (JP) | 2014-01-08 | — | — | EP | disclosed |
| CN-103391944-A | Novel macrolide intermediate and novel production process | MEIJI SEIKA PHARMA CO LTD | 2013-11-13 | — | — | CN | disclosed |
| US-6596738-B1 | Inhibiting activity to adenosine deaminase (hereinafter described as ADA) An adenosine deaminase inhibiting agent comprising a compound of the formula (I): | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-22 | — | — | US | disclosed |
| EP-0771196-B1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1999-12-08 | — | — | EP | disclosed |
| US-5717109-A | CARBOXYCYCLOPROPYL GLYCINE DERIVATIVES; USEFUL FOR TREATMENT OF ACUTE OR CHRONIC NEURODEGENERATIVE CONDITIONS, AND AS ANTIPSYCHOTIC, ANTICONVULSANT, ANALGESIC, ANXIOLYTIC, ANTIDEPRESSANT AND ANTI-EMETIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-02-10 | — | — | US | disclosed |
| EP-0279990-A2 | Use of heterocyclic derivatives in the treatment of cognitive disorders | GLAXO GROUP LIMITED (GB) | 1988-08-31 | — | — | EP | disclosed |
| EP-0266899-A2 | Indole derivatives | GLAXO GROUP LIMITED (GB) | 1988-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140039171-A1 | NOVEL MACROLIDE INTERMEDIATE AND NOVEL PRODUCTION PROCESS | MRPL21, PIGS, CYP51A1 | HTR2A 2225/4885GPR84 2353/4885KEAP1 3524/4885 |
| US-12454502-B2 | Synthesis of deuterated aldehydes | ADH1C, ADH1A, CBR1 | HTR2A 1354/4885GPR84 3563/4885KEAP1 399/4885 |
| US-20220356139-A1 | SYNTHESIS OF DEUTERATED ALDEHYDES | ADH1C, ADH1A, CBR1 | HTR2A 1354/4885GPR84 3563/4885KEAP1 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.